Denmark· DK-28107024023
Buprenorphin Carefarm
A buprenorphine product containing buprenorphinhydrochlorid, registered in Denmark by Orifarm A/S. The same ATC class is registered in 13 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Buprenorphine is registered in 13 of 19 countries.
Countries holding a registration under ATC N02AE01 (buprenorphine), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Buprenorphine · ATC N02AE01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of buprenorphine costs, country by country.
Normalised to the WHO defined daily dose (1.2 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Buprenorphine · price per daily dose (1.2 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.77
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- BUPRENORPHINHYDROCHLORID
- Manufacturer
- Orifarm A/S
- Country
- Denmark (DK)
- ATC code
- N02AE01
- ATC class
- Buprenorphine
- Defined daily dose
- 1.2 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28107024023
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
378 interactions on record for buprenorphine.
Graded by severity as the source publishes them — 59 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Buprenorphine · interactions on record
378 records
- 59 severe
- 253 moderate
- 2 minor
- 52 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- DronabinolA04AD10severe
12 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N02AE01
Buprenorphine, as other registers publish it.
- NorwayBugnantoSandoz - København
- NorwayBugnantoSandoz - København
- NorwayBugnantoSandoz - København
- NorwayBugnantoSandoz - København
- NorwayBugnantoSandoz - København
- PolandBunondolZakłady Farmaceutyczne POLPHARMA S.A.
- PolandBunondolZakłady Farmaceutyczne POLPHARMA S.A.
- PolandBunondolZakłady Farmaceutyczne POLPHARMA S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e8987028-0ba0-4718-9e7e-e98c3a8d7fee GET /v1/drugs/e8987028-0ba0-4718-9e7e-e98c3a8d7fee?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "resoribletter, sublinguale",
"source": "dkma",
"strength": "400 mikrogram",
"auth_role": "DKMA",
"dk_drugid": "28107024023",
"substance": "BUPRENORPHINHYDROCHLORID",
"auth_procedure": "Par-Imp",
"in_medicinpriser": false,
"registration_date_serial": "45195"
}See everything about buprenorphine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.